Jieer Ying
Zhejiang Cancer Hospital · Cancer Hospital of The University of Chinese Academy of Science
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jieer Ying as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:48 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07855757 · Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Cancer With Malignant AscitesZhejiang Cancer Hospital · active not recruiting · Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer, Ascites, Malignant · principal investigator
- Ph1/Ph2NCT06650332 · Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ PatientsZhejiang Cancer Hospital · recruiting · Metastatic HER2 Positive Gastroesophageal Junction Cancer · principal investigator
- Ph1/Ph2NCT06572319 · Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ PatiensZhejiang Cancer Hospital · recruiting · HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph2NCT06393166 · Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic CancerZhejiang Cancer Hospital · unknown · Non-Resectable Pancreas Carcinoma · principal investigator
- Ph2NCT06383533 · Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct AdenocarcinomaZhejiang Cancer Hospital · unknown · Bile Duct Adenocarcinoma Non-Resectable, HER2 Gene Mutation · principal investigator
- Ph2NCT06092645 · Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct AdenocarcinomaZhejiang Cancer Hospital · unknown · Bile Duct Adenocarcinoma · principal investigator
- Ph2NCT06046963 · Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant AscitesZhejiang Cancer Hospital · unknown · Gastric Cancer, Peritoneal Metastases, Ascites, Malignant · principal investigator
- Ph2NCT05934331 · A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyLaNova Medicines Zhejiang Co., Ltd. · recruiting · Malignant Neoplasms of Digestive Organs · principal investigator
- Ph2NCT05864105 · PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaBiotheus Inc. · completed · Hepatocellular Carcinoma · principal investigator
- Ph2NCT05559775 · A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard TherapyZhejiang Cancer Hospital · unknown · Gastrointestinal Cancer · principal investigator
- Ph1/Ph2NCT05214482 · A Study of AK112 in Advanced Malignant TumorsAkeso · completed · Advanced Malignant Tumors · principal investigator
- Ph1NCT04718402 · A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric CarcinomaCSPC ZhongQi Pharmaceutical Technology Co., Ltd. · terminated · Advanced Gastric Carcinoma · principal investigator
- Ph2NCT04300959 · Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract CancerZhejiang Cancer Hospital · unknown · Biliary Tract Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:48 UTC. The ranking covers the 200 most relevant of 88 PubMed records, and a shared surname and initials can bring in a namesake. All 88 on PubMed
- 363 citationsRCR 20.1
- Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.J Thorac Oncol · 2020356 citationsRCR 12.7
- Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.Clin Cancer Res · 2021256 citationsRCR 14.2
- Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.Lancet Oncol · 2023248 citationsRCR 20.9
- Circulating factors associated with sarcopenia during ageing and after intensive lifestyle intervention.J Cachexia Sarcopenia Muscle · 2019227 citationsRCR 10.7
- Elemental diet induces histologic response in adult eosinophilic esophagitis.Am J Gastroenterol · 2013226 citationsRCR 8.2
- Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.J Clin Oncol · 2023186 citationsRCR 16.1
- Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.Cancer Commun (Lond) · 2021185 citationsRCR 9.8
- Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol · 2020182 citationsRCR 7.2
- 175 citationsRCR 21.7